The treatment of castration-resistant prostate cancer;A kasztrációrezisztens prosztatadaganatok onkológiai kezelése

Magyar Onkologia

Volumn 56, Issue 4, 2012, Pages 219-228

  Ágota, Petrányi ^a  

^a Egyesített Szent István És Szent László Kórház Onkológiai Osztály ^*  (Hungary)

Author keywords

Bone targeting therapy; Castration resistant prostate cancer; Chemotherapy; Immunotherapy; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ABIRATERONE; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANE DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CANCER VACCINE; DOCETAXEL; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN TYROSINE KINASE; SIPULEUCEL T; TAXOID; TISSUE EXTRACT; TNFSF11 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; DISEASE MANAGEMENT; MOLECULAR DYNAMICS; BONE TUMOR; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METASTASIS; METHODOLOGY; MOLECULARLY TARGETED THERAPY; ORCHIECTOMY; PROSTATE TUMOR; REVIEW; TREATMENT FAILURE;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANDROSTENOLS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES, ANTISENSE; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RANK LIGAND; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TAXOIDS; TISSUE EXTRACTS; TREATMENT FAILURE;

EID: 84873376754     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Adamo V, Noto L, Franchina T, et al. Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 3:73, 2012
2. Agarwal N, Sonpavde G, Sartor O. Cabazitaxel for the treatment of castration-resistant prostate cancer. Future Oncol 7:15-24, 2011
3. Aller AW, Kraus LA, Bissery MC. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines [abstract]. Proc Am Assoc Cancer Res 41:303, 2000
4. Ansari J, Hussain SA, Zarkar A, et al. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 20:891-896, 2008
5. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742-3748, 2009
6. Basch EM, Somerfield MR, Beer TM, et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 25:5313-5318, 2007 (Pubitemid 350232264)
7. Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168:2439-2443, 2002 (Pubitemid 35402635)
8. Berthold DR, Pond GR, de Wit R, et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19:1749-1753, 2008
9. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008
10. Bodoky Gy, Kopper L. Urogenitális onkológia. Medicina Könyvkiadó, Budapest 2011
11. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-Associated proteins. J Natl Cancer Inst 92:1295-1302, 2000 (Pubitemid 30662093)
12. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959-1966, 2007 (Pubitemid 350036854)
13. Cha E, Fong L. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther 12:77-85, 2010
14. Chang SS, Kibel AS. The role of systemic cytotoxic therapy for prostate cancer. BJU Int 103:8-17, 2009
15. Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247-4254, 2010
16. Chin, JL, Srigley J, Mayhew LA, et al. Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: evidentiary base. Can Urol Assoc J 4:13-25, 2010
17. Dagher R, Li N, Abraham S, et al. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 10:8147-8151, 2004 (Pubitemid 40053372)
18. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22: 2532-2539, 2004 (Pubitemid 41103740)
19. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147-1154, 2010
20. Decker KF, Zheng D, He Y, et al. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res 2012 [Epub ahead of print]
21. Eymard JC, Oudard S, Gravis G, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 106:974-978, 2010
22. Ferrero JM, Chamorey E, Oudard S, et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 107:738-745, 2006 (Pubitemid 44232666)
23. Fizazi K, Albiges L, Massard C, et al. Novel and bone-targeted agents for CRPC. Ann Oncol 23(Suppl10):x264-x267, 2012
24. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822, 2011
25. Fizazi K, Carducci MA, Smith MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 28(18s): abstr LBA4507, 2010
26. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564-1571, 2009
27. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of COU-AA-301 randomised, double-blind, placebo-controlled phase III study. Lancet Oncol 13:983-992, 2012
28. Fizazi K, Yang J, Peleg S, et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9:2587-2597, 2003 (Pubitemid 36842101)
29. Hardwick J. Cabazitaxel for prostate cancer: patient preparation and ongoing care. Br J Nurs 21:S13-17, 2012
30. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113:975-984, 2008
31. Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17:3160-3166, 1999 (Pubitemid 29470646)
32. Huggins C, Hodges CV. Studies on prostate cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941
33. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55:1112-1123, 2009
34. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a doubleblind, placebo-controlled, randomized phase II trial. BJU Int 106:966-973, 2010
35. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
36. Joly F, Tannock IF. Chemotherapy for patients with hormone-refractory prostate cancer. Ann Oncol 15:1582-1584, 2004 (Pubitemid 39562597)
37. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506-2513, 1999 (Pubitemid 29368252)
38. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
39. Kim SJ, Kim SI. Current treatment strategies for castration-resistant prostate cancer. Korean J Urol 52:157-165, 2011
40. Kolodziej M, Neubauer MA, Rousey SR, et al. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer. Clin Genitourin Cancer 5:155-161, 2006
41. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28:207-214, 2009
42. Logothetis C, Tu SM, Navone N. Targeting prostate cancer bone metastases. Cancer 97(3 Suppl):785-788, 2003 (Pubitemid 36125813)
43. Loriot Y, Massard C, Fizazi K. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Ann Oncol 23:1085-1094, 2012
44. Loriot Y, Massard C, Gross-Goupil M, et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 46:1770-1772, 2010
45. Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Invest Drugs 18:1001-1011, 2009
46. Oh WK, Manola J, Babcic V, et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 67:1235-1240, 2006 (Pubitemid 43818095)
47. Pal SK, Sartor O. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 68:103-105, 2011
48. Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 5:395-402, 2010
49. Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Dev Ther 5:117-124, 2011
50. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004 (Pubitemid 39315318)
51. Picus J, Halabi S, Kelly WK, et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 117:526-533, 2011
52. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55:300-318, 2005 (Pubitemid 41377334)
53. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489-1495, 2010
54. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29:3651-3658, 2011
55. Ryan CJ, Smith MR, De Bono JS, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 30(Suppl): abstr LBA4518, 2012
56. Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 4:18, 2011
57. Scher HI, Beer TM, Higano CS, et al. Prostate Cancer Foundation/ Department of Defense Prostate Cancer Clinical Trials Consortium: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375:1437-1446, 2010
58. Scher HI, Fizazi K, Saad F, et al. Effect of MDV3100, an androgen receptor signalling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol 30(suppl 5): abstr LBA1, 2012
59. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253-8261, 2005 (Pubitemid 46211563)
60. Shepard DR, Dreicer R. Zibotentan for the treatment of castrate-resistant prostate cancer. Expert Opin Investig Drugs 19:899-908, 2010
61. Slovin SF, Beer TM, Higano CS, et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 27(suppl 5):15s (abstr 5138), 2009
62. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025-1033, 2004 (Pubitemid 41095034)
63. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13:3883-3891, 2007 (Pubitemid 47037595)
64. Sonpavde G, Sternberg CN. Satraplatin for the therapy of castration-resistant prostate cancer. Future Oncol 5:931-940, 2009
65. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 21:319-324, 2010
66. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
67. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996 (Pubitemid 26185452)
68. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790, 2009
69. Vaishampayan UN, Marur S, Heilbrun LK, et al. Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J Urol 182:317-323, 2009
70. Vishnu P, Tan WW. Update on options for treatment of metastatic castration resistant prostate cancer. Onco Targets Ther 3:39-51, 2010
71. W.atson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107:16759-16765, 2010
72. Wu Y, Rosenberg JE, Taplin ME. Novel agents and new therapeutics in castration-resistant prostate cancer. Curr Opin Oncol 23:290-296, 2011
73. Yu EY, Massard C, Gross ME, et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 77:1166-1171, 2011